Join
Live feed
·
PRReleasevia Quantisnow
Nexalin Technology Inc. logo

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

ByQuantisnow·Wall Street's wire, on your screen.
NXL· Nexalin Technology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXL (Nexalin Technology Inc.) and more on Quantisnow.